Long-term therapy with inhaled iloprost in patients with pulmonary hypertension

Respiratory Medicine

Volumn 104, Issue 5, 2010, Pages 731-740

  Olschewski, Horst ^a,b   Hoeper, Marius M ^c   Behr, Juergen ^d   Ewert, Ralf ^e,f   Meyer, Andreas ^g   Borst, Mathias M ^h,i   Winkler, Jörg ^j   Pfeifer, Michael ^k   Wilkens, Heinrike ^l   Ghofrani, Hossein Ardeschir ^a   Nikkho, Sylvia ^m   Seeger, Werner ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^g Klinik für Pneumologie   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ CARITAS KRANKENHAUS   (Germany)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k Donaustauf Hospital   (Germany)

^l SAARLAND UNIVERSITY   (Germany)

^m BAYER PHARMA AG   (Germany)

more..

Author keywords

Hypertension; Inhaled iloprost; Long term treatment; pulmonary; Pulmonary arterial hypertension; Survival

Indexed keywords

ILOPROST; PLACEBO; VASODILATOR AGENT;

ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; INFECTION; LONG TERM CARE; MALE; NAUSEA; NEBULIZER; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THORAX PAIN; TRISMUS; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION; VERTIGO; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS; YOUNG ADULT;

EID: 77951621266     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.01.008     Document Type: Article

References (33)

1. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., and Brundage B.H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 5 (1996 Feb 1) 296-302
2. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., Keogh A., Oudiz R., Frost A., Blackburn S.D., Crow J.W., and Rubin L.J. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 6 (2002 Mar 15) 800-804
3. Galie N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., Sitbon O., Torbicki A., Delcroix M., Naeije R., Hoeper M., Chaouat A., Morand S., Besse B., and Simonneau G. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 9 (2002 May 1) 1496-1502
4. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., Nikkho S., Speich R., Hoeper M.M., Behr J., Winkler J., Sitbon O., Popov W., Ghofrani H.A., Manes A., Kiely D.G., Ewert R., Meyer A., Corris P.A., Delcroix M., Gomez-Sanchez M., Siedentop H., and Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 5 (2002 Aug 1) 322-329
5. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002 Mar 21) 896-903
6. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., Naeije R., and Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 10 (2006 May 16) 2049-2056
7. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., Badesch D.B., McGoon M.D., McLaughlin V.V., Roecker E.B., Gerber M.J., Dufton C., Wiens B.L., and Rubin L.J. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 23 (2008 Jun 10) 3010-3019
8. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., and Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 20 (2005 Nov 17) 2148-2157
9. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Shapiro S., White R.J., Chan M., Beardsworth A., Frumkin L., and Barst R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119 22 (2009 Jun 9) 2894-2903
10. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 6 (1994 Sep 15) 409-415
11. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 12 (2002 Sep 17) 1477-1482
12. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., Rainisio M., and Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 4 (2002 Aug 21) 780-788
13. Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., and Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124 9 (1996 May 1) 820-824
14. Olschewski H., Ghofrani H.A., Walmrath D., Temmesfeld-Wollbruck B., Grimminger F., and Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 24 6 (1998 Jun) 631-634
15. Olschewski H., Ghofrani H.A., Walmrath D., Schermuly R., Temmesfeld-Wollbruck B., Grimminger F., and Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 2 (1999 Aug) 600-607
16. Olschewski H., Ghofrani H.A., Schmehl T., Winkler J., Wilkens H., Hoper M.M., Behr J., Kleber F.X., and Seeger W. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132 6 (2000 Mar 21) 435-443
17. Olschewski H., Rohde B., Behr J., Ewert R., Gessler T., Ghofrani H.A., and Schmehl T. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124 4 (2003 Oct) 1294-1304
18. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., Badesch D.B., Barst R.J., Hsu H.H., and Rubin L.J. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 11 (2006 Aug 31) 1257-1263
19. Guyatt G.H., Sullivan M.J., Thompson P.J., Fallen E.L., Pugsley S.O., Taylor D.W., and Berman L.B. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132 8 (1985 May 15) 919-923
20. Borg G. Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test. Int J Sports Med 3 3 (1982 Nov 1) 153-158
21. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 3 (1990 Dec) 199-208
22. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 6 (1984 Jun) 751-758
23. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 5 (1991 Sep 1) 343-349
24. Oudiz R.J., Widlitz A., Beckmann X.J., Camanga D., Alfie J., Brundage B.H., and Barst R.J. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 126 1 (2004 Jul) 90-94
25. Provencher S., Sitbon O., Humbert M., Cabrol S., Jais X., and Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 5 (2006 Mar) 589-595
26. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., Rainisio M., Simonneau G., and Rubin L.J. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 2 (2005 Feb) 244-249
27. Barst R.J., Galie N., Naeije R., Simonneau G., Jeffs R., Arneson C., and Rubin L.J. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil16. Eur Respir J 28 6 (2006 Dec) 1195-1203
28. Lang I., Gomez-Sanchez M., Kneussl M., Naeije R., Escribano P., Skoro-Sajer N., and Vachiery J.L. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129 6 (2006 Jun) 1636-1643
29. Higenbottam T., Butt A.Y., McMahon A., Westerbeck R., and Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80 2 (1998 Aug) 151-155
30. Higenbottam T.W., Butt A.Y., Dinh-Xuan A.T., Takao M., Cremona G., and Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79 2 (1998 Feb) 175-179
31. Kuhn K.P., Byrne D.W., Arbogast P.G., Doyle T.P., Loyd J.E., and Robbins I.M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 4 (2003 Mar 15) 580-586
32. Opitz C.F., Wensel R., Winkler J., Halank M., Bruch L., Kleber F.X., Hoffken G., Anker S.D., Negassa A., Felix S.B., Hetzer R., and Ewert R. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26 18 (2005 Sep) 1895-1902
33. Hoeper M.M., Leuchte H., Halank M., Wilkens H., Meyer F.J., Seyfarth H.J., Wensel R., Ripken F., Bremer H., Kluge S., Hoeffken G., and Behr J. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 4 (2006 Oct) 691-694